IRIS
ATZENI, Fabiola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.576
EU - Europa 8.772
AS - Asia 6.105
SA - Sud America 2.432
Continente sconosciuto - Info sul continente non disponibili 652
AF - Africa 223
OC - Oceania 12
Totale 30.772
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.191
RU - Federazione Russa 5.022
SG - Singapore 2.692
BR - Brasile 2.064
CN - Cina 1.463
IE - Irlanda 1.244
IT - Italia 801
HK - Hong Kong 730
SE - Svezia 639
VN - Vietnam 315
FR - Francia 287
DE - Germania 207
GB - Regno Unito 146
IN - India 143
CA - Canada 133
AR - Argentina 128
BD - Bangladesh 121
PL - Polonia 115
IQ - Iraq 81
MX - Messico 79
ZA - Sudafrica 69
TR - Turchia 67
NL - Olanda 58
ID - Indonesia 50
FI - Finlandia 49
EC - Ecuador 48
VE - Venezuela 47
UZ - Uzbekistan 46
JP - Giappone 44
PK - Pakistan 44
CO - Colombia 40
UA - Ucraina 34
AT - Austria 31
CR - Costa Rica 31
MA - Marocco 28
EG - Egitto 27
ES - Italia 27
JM - Giamaica 27
CL - Cile 26
PY - Paraguay 26
SA - Arabia Saudita 26
AE - Emirati Arabi Uniti 25
BE - Belgio 24
JO - Giordania 22
KE - Kenya 22
BO - Bolivia 21
IL - Israele 21
NP - Nepal 20
PH - Filippine 19
KZ - Kazakistan 18
PE - Perù 18
AZ - Azerbaigian 16
DZ - Algeria 16
TN - Tunisia 16
TT - Trinidad e Tobago 15
HN - Honduras 14
IR - Iran 14
MY - Malesia 14
PA - Panama 14
GT - Guatemala 12
KG - Kirghizistan 12
NI - Nicaragua 12
LB - Libano 11
OM - Oman 11
SV - El Salvador 11
UY - Uruguay 11
PS - Palestinian Territory 10
RO - Romania 10
TH - Thailandia 10
DK - Danimarca 9
DO - Repubblica Dominicana 9
PT - Portogallo 9
QA - Qatar 9
SN - Senegal 9
SY - Repubblica araba siriana 8
AL - Albania 7
BB - Barbados 7
BY - Bielorussia 7
CI - Costa d'Avorio 7
ET - Etiopia 7
AM - Armenia 6
AU - Australia 6
CH - Svizzera 6
CZ - Repubblica Ceca 6
EU - Europa 6
PR - Porto Rico 6
AO - Angola 5
BH - Bahrain 5
EE - Estonia 5
GE - Georgia 5
KR - Corea 5
RS - Serbia 5
TW - Taiwan 4
BG - Bulgaria 3
BS - Bahamas 3
BZ - Belize 3
CW - ???statistics.table.value.countryCode.CW??? 3
CY - Cipro 3
GA - Gabon 3
GP - Guadalupe 3
Totale 30.064
Salva come PNG Salva come JPEG
Città #
Moscow 1.751
Ashburn 1.723
Singapore 1.542
Dublin 1.241
Chandler 1.009
Dallas 973
Hong Kong 717
San Jose 711
Beijing 595
Nyköping 456
Council Bluffs 440
New York 381
Princeton 271
Jacksonville 254
Dearborn 245
The Dalles 230
Medford 229
Lauterbourg 214
Los Angeles 207
Des Moines 206
São Paulo 174
Cambridge 166
Santa Clara 153
Redondo Beach 116
Buffalo 110
Ho Chi Minh City 103
Warsaw 103
Messina 101
Rio de Janeiro 85
Rome 78
Ann Arbor 74
Hanoi 70
Munich 70
Orem 70
Atlanta 66
North Bergen 66
Wilmington 63
Frankfurt am Main 60
Tianjin 60
Belo Horizonte 59
Milan 59
Pune 59
Guangzhou 51
Brooklyn 49
Nanjing 43
Tashkent 42
Phoenix 41
Tokyo 41
Shenyang 40
Chicago 38
San Francisco 36
Denver 35
Seattle 34
Jinan 33
Naples 33
Montreal 32
Baghdad 31
Brasília 30
Nuremberg 30
Boardman 29
London 29
Johannesburg 28
Porto Alegre 28
Buenos Aires 26
Amsterdam 25
Campinas 24
Catania 23
Shanghai 23
Turin 23
Washington 23
Chennai 22
Houston 22
Mexico City 22
Columbus 21
Curitiba 21
Falls Church 21
Turku 21
Brussels 20
Florence 20
Salvador 20
Boston 19
Dhaka 19
Ningbo 19
Philadelphia 19
San Mateo 19
Amman 18
Haikou 18
Hebei 18
Kingston 18
Nairobi 18
Norwalk 18
San José 18
Cape Town 17
Fortaleza 17
Guayaquil 17
Vienna 17
Zhengzhou 17
Caxias do Sul 16
Charlotte 16
Guarulhos 16
Totale 16.844
Salva come PNG Salva come JPEG
Nome #
EULAR revised recommendations for the management of fibromyalgia 450
Comparison of Efficacy of Ketoprofen and Ibuprofen in Treating Pain in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis 425
International, multidisciplinary Delphi consensus recommendations on non-pharmacological interventions for fibromyalgia 240
2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases 224
CORRELATION BETWEEN DISEASE ACTIVITY AND CARDIOVASCULAR PARAMETERS IN PATIENTS WITH ANKYLOSING SPONDYLITIS 215
Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors 203
Algo-dysfunctional syndromes: a critical digest of the recent literature 202
CARDIOVASCULAR EVALUATION USING NON-INVASIVE IMAGING METHODS IN PATIENTS WITH ANKYLOSING SPONDYLITIS BEFORE AND AFTER 12 MONTHS OF TREATMENT WITH ANTI-TNF DRUGS 199
A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis 198
A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data 197
Central nervous system involvement in rheumatoid arthritis patients and the potential implications of using biological agents 196
Anti-tumour necrosis factor-α antibodies and B cell homeostasis in human inflammatory bowel diseases 185
Certainties and uncertainties concerning the contribution of pericytes to the pathogenesis of systemic sclerosis 183
Biomarkers in Rheumatoid Arthritis 172
BODY MASS INDEX, SMOKING STATUS AND RESPONSE TO RITUXIMAB IN RHEUMATOID ARTHRITIS: A REAL-LIFE STUDY. 170
A Review of Chronic Musculoskeletal Pain: Central and Peripheral Effects of Diclofenac 170
Cancer risk and tumour necrosis factor inhibitors in patients with inflammatory arthritis 164
Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: A case series 160
Assessment of enthesis in patients with psoriatic arthritis and fibromyalgia using clinical examination and ultrasound 160
CLINICAL AND ULTRASONOGRAPHIC EVALUATION IN A COHORT OF SUSTAINED REMISSION RHEUMATOID ARTHRITIS PATIENTS AFTER STOPPING BIOLOGIC THERAPY: A SINGLE CENTER EXPERIENCE , 158
Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study 158
Recurrent intracranial hemorrhage and cerebral venous sinus thrombosis: an atypical case of Neuro-Behçet’s Syndrome 158
Paradoxical Expansion of Th1 and Th17 Lymphocytes in Rheumatoid Arthritis Following Infliximab Treatment: a Possible Explanation for a Lack of Clinical Response 151
A proteinuria cut-off level of 0.7 g /day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: Data from the MAINTAIN Nephritis Trial 148
B Lymphocyte intestinal homing in inflammatory bowel disease 148
RELATIONSHIP BETWEEN ULTRASONOGRAPHIC SALIVARY GLANDS ABNORMALITIES AND SUBCLINICAL CARDIOVASCULAR INVOLVEMENT IN PATIENTS WITH PRIMARY SJÖGREN SYNDROME 148
Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: A one-year prospective study 144
Anti-adalimumab and anti-certolizumab antibodies titers after discontinuation of adalimumab: Two case reports 142
An update on emerging drugs for fibromyalgia treatment 142
A possible link between ankylosing spondylitis and periodontitis: A systematic review and meta-analysis 141
The neuropathic pain features in Psoriatic Arthritis: a cross-sectional evaluation of prevalence and associated factors 138
Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients 137
The microbiome in connective tissue diseases and vasculitides: An updated narrative review 135
Biological agents in rheumatoid arthritis: A cross-link between immune tolerance and immune surveillance 135
A Proposed Serum Calprotectin IgG Cut-Off Level for Diagnosing Inflammatory Arthritis 134
MEASUREMENT OF SERUM ALPHA-KLOTHO IN SYSTEMIC SCLEROSIS PATIENTS: RESULTS FROM A PIVOTAL STUDY. 134
Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab 134
Are the ACR 2010 diagnostic criteria for fibromyalgia better than the 1990 criteria? 133
Cross Cultural Adaptation and Validation of Italian Version of the Leeds Assessment of Neuropathic Symptoms and Signs Scale and Pain DETECT Questionnaire for the Distinction between Nociceptive and Neuropathic Pain 132
Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents 131
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry 130
An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis 130
Systemic rheumatic diseases: from biological agents to small molecules 128
From autoinflammation to autoimmunity: old and recent findings 126
Safety of Abatacept in Rheumatoid Arthritis with Serologic Evidence of Past or Present Hepatitis B Virus Infection 125
Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs: a narrative review 125
One year in review 2019: fibromyalgia 124
Hyperbaric oxygen treatment of fibromyalgia: a prospective observational clinical trial 124
Mortality risk factors in primary Sjögren syndrome: a real-world, retrospective, cohort study 122
PLA1/A2 polymorphism of the platelet glycoprotein receptors IIIA in Behçet's disease 122
Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis 122
Measuring psoriatic disease in clinical practice. An expert opinion position paper 120
Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study 120
Impaired lung transfer factor in fibromyalgia syndrome 120
Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment 119
What are the dangers of biological therapy discontinuation or dose reduction strategies when treating rheumatoid arthritis? 118
Ultrasonographyc Evaluation of Metacarpophalangeal Joints Can be Useful in the Differential Diagnosis of Early Rheumatoid Arthritis and Early Spondyloarthritis. A Monocentric Preliminary Study 118
TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same? 118
Longterm retention of tumor necrosis factor-α inhibitor therapy in a large Italian cohort of patients with rheumatoid arthritis from the GISEA Registry: An appraisal of predictors 117
Retrotransposons shuttling genetic and epigenetic information from the nuclear to the mitochondrial compartment: Do they play a pathogenetic role in scleroderma? 116
Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register 116
Anti-citrullinated peptide antibodies and rheumatoid factor isotypes in the diagnosis of rheumatoid arthritis: An assessment of combined tests 116
Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks 115
Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: Real-life data from the LORHEN registry 115
Immunogenicity and autoimmunity during anti-TNF therapy 115
Chronic widespread pain in the spectrum of rheumatological diseases 114
Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction. 114
Noninvasive imaging methods for evaluating cardiovascular involvement in patients with rheumatoid arthritis before and after anti-TNF drug treatment 114
EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update 113
CC chemokine receptor 5 polymorphism in Italian patients with Beḩet's disease 113
Co-Occurrence and Characteristics of Patients With Axial Spondyloarthritis Who Meet Criteria for Fibromyalgia: Results From a UK National Register 113
Psoriatic arthritis: From pathogenesis to pharmacologic management 113
Malar rash is a predictor of subclinical airway inflammation in patients with systemic lupus erythematosus: a pilot study 112
EULAR recommendations for management of fibromyalgia 112
How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project) 111
Efficacy of Cannabis Flos in Patients with Fibromyalgia: A Monocentric 111
Differential Diagnosis of Vasovagal Syncope: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. 110
Patients Failing to Fulfill 2016 Criteria for Fibromyalgia Represent a Truly Different Population Subset 110
Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren’s syndrome at diagnosis in 8310 patients: A cross-sectional study from the Big Data Sjögren’s Project Consortium 109
Autoantibody profile during short-term infliximab treatment for Crohn's disease: A prospective cohort study 108
Measurement of Serum Klotho in Systemic Sclerosis 107
Pain in systemic sclerosis 107
AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS) 107
Prescribing motivations and patients’ characteristics related to the use of biologic drugs in adult-onset Still’s disease: analysis of a multicentre “real-life” cohort 107
Adding medical cannabis to standard analgesic treatment for fibromyalgia: a prospective observational study 107
Web/Internet-based telemonitoring of a randomized controlled trial evaluating the time-integrated effects of a 24-week multicomponent intervention on key health outcomes in patients with fibromyalgia 106
Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry 106
DOSE REDUCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS RESPONDING TO THE STANDARD RITUXIMAB REGIMEN. 105
Efficacy and Safety of Biosimilar and Originator Etanercept in Rheumatoid Arthritis Patients: Real-Life Data 105
Transcription Factors 105
Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial 104
Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients 104
Targeting the interleukin-5 pathway in EGPA: Evidence, uncertainties and opportunities 103
Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: cause for concern? 103
PREVALENCE OF CHRONIC WIDESPREAD PAIN IN SSC PATIENTS: PRELIMINARY DATA 103
The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts 103
Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies 103
Cardiovascular Imaging Techniques in Systemic Rheumatic Diseases 102
Controlled-release pregabalin in the treatment of fibromyalgia 101
Infections and Biological Therapy in Patients with Rheumatic Diseases 101
Totale 13.881
Salva come PNG Salva come JPEG
Categoria #
all - tutte 121.765
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 121.765
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.077 0 0 0 0 96 21 27 51 36 55 169 622
2022/20233.443 311 221 155 315 169 347 19 199 1.556 14 110 27
2023/20241.113 94 133 188 83 69 383 7 33 4 32 7 80
2024/20254.812 74 44 93 294 148 152 146 1.060 1.340 335 395 731
2025/202613.263 484 947 1.149 759 1.131 3.036 1.653 1.444 1.375 634 258 393
2026/20274.757 537 1.274 1.200 1.699 47 0 0 0 0 0 0 0
Totale 30.772